Biocon gains as its arm inks agreement to purchase 7.69% stake in Syngene International

10 Sep 2014 Evaluate

Biocon is currently trading at Rs. 508.55, up by 6.50 points or 1.29% from its previous closing of Rs. 502.05 on the BSE.

The scrip opened at Rs. 504.00 and has touched a high and low of Rs. 512.00 and Rs. 502.70 respectively. So far 1,32,000 shares were traded on the counter.

The BSE group 'A ' stock of face value Rs. 5 has touched a 52 week high of Rs. 553.70 on 04-Jul-2014 and a 52 week low of Rs. 319.00 on 17-Sep-2013.

Last one week high and low of the scrip stood at Rs. 512.00 and Rs. 479.30 respectively. The current market cap of the company is Rs. 10,171.00 crore.

The promoters holding in the company stood at 60.97% while Institutions and Non-Institutions held 20.05% and 18.97% respectively.

Biocon’s wholly owned subsidiary - Biocon Research (BRL), has entered into an agreement with GE Equity International Mauritius, a subsidiary of GE Capital Corporation (GE Capital), to purchase the latter’s investment in Biocon’s research services subsidiary, Syngene International for an agreed consideration of Rs 215.38 crore. GE Capital had a 7.69% stake in Syngene.

Syngene offers integrated drug discovery and development services with capabilities in medicinal chemistry, biology, in vivo pharmacology and toxicology.

Biocon is India’s largest and Asia's leading biotechnology company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

390.25 -5.00 (-1.27%)
29-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.50
Dr. Reddys Lab 1268.60
Cipla 1494.40
Zydus Lifesciences 904.00
Lupin 2079.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×